4.6 Article

Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)

Journal

THORAX
Volume 76, Issue 1, Pages 86-88

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2020-215705

Keywords

exhaled airway markers; respiratory infection; viral infection

Funding

  1. Science Foundation Ireland COVID Rapid Response Call grant [20/COV/0109]
  2. North East Cancer Research and Education Trust (NECRET) [1696]

Ask authors/readers for more resources

Exhaled breath condensate (EBC) RT-PCR for SARS-CoV-2 genes showed a higher detection rate compared to nasopharyngeal swabs (NPS) in cases with false negatives, indicating its potential in improving the diagnosis of COVID-19.
False negatives from nasopharyngeal swabs (NPS) using reverse transcriptase PCR (RT-PCR) in SARS-CoV-2 are high. Exhaled breath condensate (EBC) contains lower respiratory droplets that may improve detection. We performed EBC RT-PCR for SARS-CoV-2 genes (E, S, N, ORF1ab) on NPS-positive (n=16) and NPS-negative/clinically positive COVID-19 patients (n=15) using two commercial assays. EBC detected SARS-CoV-2 in 93.5% (29/31) using the four genes. Pre-SARS-CoV-2 era controls (n=14) were negative. EBC was positive in NPS negative/clinically positive patients in 66.6% (10/15) using the identical E and S (E/S) gene assay used for NPS, 73.3% (11/15) using the N/ORF1ab assay and 14/15 (93.3%) combined.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available